Eltrombopag for the treatment of idiopathic thrombocytopenic purpura

References

• George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood88(1), 3–40 (1996).
   PubMed Web of Science ®Google Scholar
• Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch. Intern. Med.160(11), 1630–1638 (2000).
   PubMed Web of Science ®Google Scholar
• Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood97(9), 2549–2554 (2001).
   PubMed Web of Science ®Google Scholar
• Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin. Proc.79(4), 504–522 (2004).
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood106(7), 2244–2251 (2005).
   PubMed Web of Science ®Google Scholar
• George JN. Management of patients with refractory immune thrombocytopenic purpura. J. Thromb. Haemost.4(8), 1664–1672 (2006).
   PubMed Web of Science ®Google Scholar
• Bussel J. Treatment of immune thrombocytopenic purpura in adults. Semin. Hematol.43(3 Suppl. 5), S3–S10 (2006).
   Google Scholar
• Stasi R, Stipa E, Masi M et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am. J. Med.98(5), 436–442 (1995).
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong RS, Soo YO et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N. Engl. J. Med.349(9), 831–836 (2003).
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, Fazi P, Bernasconi S et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood109(4), 1401–1407 (2007).
   PubMed Web of Science ®Google Scholar
• Scaradavou A, Woo B, Woloski BM et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood89(8), 2689–2700 (1997).
   PubMed Web of Science ®Google Scholar
• Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood104(9), 2623–2634 (2004).
   PubMed Web of Science ®Google Scholar
• Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med.146(1), 25–33 (2007).
   PubMed Web of Science ®Google Scholar
• Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur. J. Haematol. Suppl. (69), 3–8 (2008).
   PubMedGoogle Scholar
• Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br. J. Haematol.122(6), 966–974 (2003).
   PubMed Web of Science ®Google Scholar
• Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J. Thromb. Haemost.4(11), 2377–2383 (2006).
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica93(1), 98–103 (2008).
   PubMed Web of Science ®Google Scholar
• Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb. Haemost.99(1), 4–13 (2008).
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet371(9610), 395–403 (2008).
   PubMed Web of Science ®Google Scholar
• Kaushansky K. Thrombopoietin: accumulating evidence for an important biological effect on the hematopoietic stem cell. Ann. NY Acad. Sci.996, 39–43 (2003).
   PubMed Web of Science ®Google Scholar
• Geddis AE, Linden HM, Kaushansky K. Thrombopoietin: a pan-hematopoietic cytokine. Cytokine Growth Factor Rev.13(1), 61–73 (2002).
   PubMed Web of Science ®Google Scholar
• Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood89(1), 101–107 (1997).
   PubMed Web of Science ®Google Scholar
• Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood86(2), 419–431 (1995).
   PubMed Web of Science ®Google Scholar
• Fielder PJ, Gurney AL, Stefanich E et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood87(6), 2154–2161 (1996).
   PubMed Web of Science ®Google Scholar
• Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br. J. Haematol.106(2), 345–356 (1999).
   PubMed Web of Science ®Google Scholar
• Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene21(21), 3359–3367 (2002).
   PubMed Web of Science ®Google Scholar
• Siegel RS, Rae JL, Barth S et al. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am. J. Hematol.30(4), 206–212 (1989).
   PubMed Web of Science ®Google Scholar
• Louwes H, Zeinali Lathori OA, Vellenga E, de Wolf JT. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am. J. Med.106(4), 430–434 (1999).
   PubMed Web of Science ®Google Scholar
• Hoffman R, Zaknoen S, Yang HH et al. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N. Engl. J. Med.312(18), 1170–1174 (1985).
   PubMed Web of Science ®Google Scholar
• Chang M, Nakagawa PA, Williams SA et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood102(3), 887–895 (2003).
   PubMed Web of Science ®Google Scholar
• Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood93(6), 1951–1958 (1999).
   PubMed Web of Science ®Google Scholar
• Chang M, Qian JX, Lee SM et al. Tissue uptake of circulating thrombopoietin is increased in immune-mediated compared with irradiated thrombocytopenic mice. Blood93(8), 2515–2524 (1999).
   PubMed Web of Science ®Google Scholar
• Kosugi S, Kurata Y, Tomiyama Y et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br. J. Haematol.93(3), 704–706 (1996).
   PubMed Web of Science ®Google Scholar
• Porcelijn L, Folman CC, Bossers B et al. The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb. Haemost.79(6), 1101–1105 (1998).
   PubMed Web of Science ®Google Scholar
• Kuter DJ. New thrombopoietic growth factors. Blood109(11), 4607–4616 (2007).
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood98(12), 3241–3248 (2001).
   PubMed Web of Science ®Google Scholar
• Kaushansky K. Hematopoietic growth factor mimetics. Ann. NY Acad. Sci.938, 131–138 (2001).
   PubMed Web of Science ®Google Scholar
• Evangelista ML, Amadori S, Stasi R. Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use. Curr. Drug Discov. Technol.4(3), 162–173 (2007).
   PubMedGoogle Scholar
• Erickson-Miller CL, DeLorme E, Tian SS et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp. Hematol.33(1), 85–93 (2005).
   PubMed Web of Science ®Google Scholar
• Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs68(7), 901–912 (2008).
   PubMed Web of Science ®Google Scholar
• Erickson-Miller CL, DeLorme E, Iskander M et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist. Blood104 (2004) (Abstract 2909).
   Web of Science ®Google Scholar
• Jenkins JM, Williams D, Deng Y et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood109(11), 4739–4741 (2007).
   PubMed Web of Science ®Google Scholar
• Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood104 (2004) (Abstract 3888).
   Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med.357(22), 2237–2247 (2007).
   PubMed Web of Science ®Google Scholar
• Bussel J, Provan A, Shamsi T et al. Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: a Phase III study. Haematologica92(Suppl. 1) (2007) (Abstract 0390).
   Google Scholar
• Bussel JB, Cheng G, Saleh M et al. Long-term safety and efficacy of oral eltrombopag for the treatment of idiopathic thrombocytopenic purpura (ITP). Haematologica93(Suppl. 1) (2008) (Abstract 0949).
   Google Scholar
• Psaila B, Bussel JB, Vasey S et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic ITP. Haematologica93(Suppl. 1) (2008) (Abstract 0294).
   Google Scholar
• Ulich TR, del Castillo J, Senaldi G et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood87(12), 5006–5015 (1996).
   PubMed Web of Science ®Google Scholar
• Villeval JL, Cohen-Solal K, Tulliez M et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood90(11), 4369–4383 (1997).
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br. J. Haematol.139(3), 351–362 (2007).
   PubMed Web of Science ®Google Scholar
• Bussel JB, Schindler AM, Grossbard EB. R935788: a Phase II, single center, open label, efficacy and safety, ascending dose, pilot study for the treatment of adult immune thrombocytopenic purpura (ITP). Blood110(11) (2007) (Abstract 1310).
   PubMedGoogle Scholar